Wedbush restated their outperform rating on shares of Bluebird Bio Inc. (NASDAQ:BLUE) in a research note issued to investors on Wednesday morning. Wedbush currently has a $95.00 price objective on the stock.

A number of other analysts have also issued reports on the company. BMO Capital Markets assumed coverage on Bluebird Bio in a report on Thursday, November 10th. They issued a market perform rating and a $61.00 price target for the company. BTIG Research reiterated a buy rating and issued a $83.00 price target on shares of Bluebird Bio in a report on Monday, November 7th. Leerink Swann reiterated an outperform rating and issued a $80.00 price target on shares of Bluebird Bio in a report on Monday, November 7th. JPMorgan Chase & Co. reiterated a buy rating on shares of Bluebird Bio in a report on Monday, November 7th. Finally, Piper Jaffray Cos. reiterated an overweight rating and issued a $95.00 price target on shares of Bluebird Bio in a report on Friday, November 4th. One analyst has rated the stock with a sell rating, five have given a hold rating and thirteen have given a buy rating to the company. The company currently has a consensus rating of Buy and an average price target of $82.82.

Bluebird Bio (NASDAQ:BLUE) remained flat at $62.50 during mid-day trading on Wednesday. The company’s stock had a trading volume of 992,930 shares. The firm’s market capitalization is $2.33 billion. The firm’s 50-day moving average is $56.86 and its 200-day moving average is $52.51. Bluebird Bio has a 12-month low of $35.37 and a 12-month high of $95.28.

Bluebird Bio (NASDAQ:BLUE) last announced its earnings results on Wednesday, November 2nd. The company reported ($2.07) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.59) by $0.48. Bluebird Bio had a negative net margin of 3,941.72% and a negative return on equity of 30.79%. The business had revenue of $1.55 million for the quarter, compared to analysts’ expectations of $1.82 million. During the same quarter last year, the firm earned ($1.18) EPS. The firm’s quarterly revenue was up 17.4% on a year-over-year basis. Equities research analysts forecast that Bluebird Bio will post ($7.05) EPS for the current fiscal year.

In other Bluebird Bio news, insider Eric Sullivan sold 416 shares of the firm’s stock in a transaction that occurred on Monday, October 3rd. The shares were sold at an average price of $67.00, for a total value of $27,872.00. Following the completion of the transaction, the insider now owns 5,891 shares of the company’s stock, valued at approximately $394,697. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 3.50% of the stock is currently owned by company insiders.

A number of institutional investors have recently modified their holdings of BLUE. Price T Rowe Associates Inc. MD boosted its position in shares of Bluebird Bio by 37.7% in the third quarter. Price T Rowe Associates Inc. MD now owns 3,365,797 shares of the company’s stock valued at $228,134,000 after buying an additional 921,416 shares in the last quarter. Cornerstone Capital Management Holdings LLC. boosted its position in shares of Bluebird Bio by 143.8% in the third quarter. Cornerstone Capital Management Holdings LLC. now owns 7,800 shares of the company’s stock valued at $528,000 after buying an additional 4,600 shares in the last quarter. Credit Suisse AG boosted its position in shares of Bluebird Bio by 9.3% in the third quarter. Credit Suisse AG now owns 101,322 shares of the company’s stock valued at $6,869,000 after buying an additional 8,656 shares in the last quarter. Chartwell Investment Partners LLC acquired a new position in shares of Bluebird Bio during the third quarter valued at approximately $2,830,000. Finally, Baker BROS. Advisors LP acquired a new position in shares of Bluebird Bio during the third quarter valued at approximately $19,923,000.

TRADEMARK VIOLATION WARNING: “Bluebird Bio Inc. (BLUE) Given “Outperform” Rating at Wedbush” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2016/11/24/bluebird-bio-inc-blue-given-outperform-rating-at-wedbush.html.

Bluebird Bio Company Profile

bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.

5 Day Chart for NASDAQ:BLUE

Receive News & Stock Ratings for Bluebird Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluebird Bio Inc. and related stocks with our FREE daily email newsletter.